Clinical Trial

Nalmefene Implant in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn how safe either one or two nalmefene implants are after remaining implanted for 4 or 12 weeks. Additionally the pharmacokinetics (PK), how fast the drug is absorbed into the body and how long it remains in the body, will also be studies. The data collected in this healthy volunteer study will inform the Sponsor on how best to proceed with future trials in the intended patient population.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-04-07
notable Primary completion pushed: 2026-10-01 -> 2026-12 2026-04-07
Trial Details
NCT Number NCT07325279
Lead Sponsor ReacX Pharmaceuticals, Inc.
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Opioid Abuse and Addiction
Enrollment 24 participants
Start Date 2026-02-23
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-06